MedTrace Logo

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

NCT02363400 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-08-19

No results posted yet for this study

Summary

Nasopharyngeal carcinoma (NPC) is a geographically endemic, Epstein-Barr virus (EBV)-associated carcinoma of epidermoid origin. It occurs most commonly in Southern China and Southeast Asia. The NPC cells are poorly differentiated or undifferentiated with a high incidence of lymphatic and hematological dissemination. Because of the inherent anatomic constraints and a high degree of radiosensitivity, radiotherapy (RT) has been the primary treatment for NPC patients.

NPC is also a chemosensitive tumor. Various modes of combined chemoradiotherapy have been used to treat NPC patients with advanced-stage diseases during recent 20 years. However, treatment outcome for locoregionally advanced NPC is still unsatisfactory.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

MEP

Adjuvant Chemotherapy

Sponsors & Collaborators

  • Mackay Memorial Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • Kaohsiung Veterans General Hospital.

    collaborator OTHER

  • Taichung Veterans General Hospital

    collaborator OTHER

  • Koo Foundation Sun Yat-Sen Cancer Center

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Jin-Ching Lin, MD, PHD · Taichung Veterans General Hospital

  • Tsang-Wu Liu, MD · National Health Research Institutes, Taiwan

  • Jin-Ching Lin, MD, PhD · Taichung Veterans General Hospital

  • Yi-Fang Chang, MD, PhD · Mackay Memorial Hospital

  • Ching-Yun Hsieh, MD · China Medical University Hospital

  • Chia-Jui Yen Yen, MD. PhD · National Cheng-Kung University Hospital

  • Yaoh-Shiang Lin, MD · Kaohsiung Veterans General Hospital.

  • Stella Yu-Chen Tsai, MD · Sun Yat-sen University

  • Hsiao-Hui Tsou, PhD · National Health Research Institutes, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-14
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02363400 on ClinicalTrials.gov